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Background
Type 2 diabetes mellitus is a very common metabolic
disorder affecting ~200 million people worldwide [1].
Chronic complications of the disease due to poor meta-
bolic control are specifically associated with long-term
damage, dysfunction and failure of various organs, caus-
ing blindness, renal failure, amputations, and increased
risk of cardiovascular diseases [2]. Previously, we
reported a novel genetic flaw that markedly reduced the
intracellular expression of the high mobility group A1
(HMGA1) protein, and adversely affected insulin recep-
tor expression in cells and tissues, leading to human
diabetes [3]. Also, the involvement of HMGA1 in the
transcriptional regulation of genes essential in both the
inflammatory response and atherosclerosis is well
known [4]. Herein we have investigated the prevalence
of chronic complications in an elderly diabetic popula-
tion according to the expression levels of HMGA1.
Materials and methods
The study was performed in 125 elderly patients (aged
over 65 years) with type 2 diabetes consecutively attend-
ing our outpatient diabetes clinic, in Catanzaro. 50 unre-
lated age-, sex-, and ethnically-matched healthy controls
were enrolled. Periodic clinical and biochemical exami-
nations were performed on every patient, before and
during the time of investigation. Total RNA was pre-
pared from peripheral-blood mononuclear cells of
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© 2010 Chiefari et al; licensee BioMed Central Ltd.patients and controls, cDNA was synthesized and used
for HMGA1 real-time PCR (qRT-PCR) amplification.
Western blot (WB) analysis of HMGA1 was performed
on nuclear extracts from peripheral lymphomonocytes
as previously described [5,6]. The study was approved
by the local ethics committee (Comitato Etico Regione
Calabria, Azienda Ospedaleria “Mater Domini,” Catan-
zaro) and informed consent was obtained from all
individuals.
Results
In 111 patients with type 2 diabetes (88.8%), HMGA1
mRNA and protein expression levels were similar to
t h o s eo fn o r m a ls u b j e c t s( s e eF i g u r e1 ) .I nc o n t r a s t ,
HMGA1 expression was significantly reduced in 14 dia-
betic patients (11.2%) in which a mean reduction of 50%
in HMGA1 content was observed in peripheral lympho-
monocytes (see Figure 1).
HMGA1 mRNA (left) and protein (right) levels from
healthy control individuals (C), and type 2 diabetic
patients without (T2D-N) or with (T2D-R) defects in
HMGA1 expression. -actin (ACTB) and C/EBP, con-
trols. mRNA and protein abundance are expressed as
percent of maximal control value (100%). *p < 0.05 vs C.
A negative correlation was observed between reduced
HMGA1 expression and long-term diabetic complica-
tions such as retinopathy, nephropathy, neuropathy, and
cardiovascular disease (see Table 1).
Conclusions
A deficit of HMGA1 in affected diabetic patients may
confer a less severe course of the disease in terms of
long-term chronic complications of diabetes.
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Table 1
T2D-N (n = 111) T2D-R (n = 14) p* value
Patients affected 86 (77.5%) 10 (71.0%) 0.03
Long term
complications
macroangiopathic
1 36 (32.4%) 3 (21.4%) 0.03
microangiopathic
2 75 (67.6%) 8 (57.1%) 0.01
1 Include coronary heart disease, myocardial infaction and stroke.
2 Include retinopathy, nefropathy, neuropathy and foot problems.
* Yates’ chi-square test.
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